Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

Skip to main content

HDAC6 Inhibitors – Commercial Collaboration Opportunity for Neurofibromatosis Researchers

Acetylon Pharmaceuticals, a new biotech company developing technology from Harvard and the Dana-Farber Cancer Institute, is seeking neurofibromatosis researchers to assess its selective small molecule, orally administered inhibitors of HDAC6 in preclinical models of neurofibromatosis.  While Acetylon’s initial clinical priority is multiple myeloma, there is potential benefit of non-isoform specific HDAC inhibitors for treating neurofibromatosis.  Acetylon would be interested in a proposal from a leading academic group to screen the Acetylon portfolio of compounds, which could possibly lead to a clinical trial in NF as early as late 2011 or 2012, by which by time there should be Phase Ia clinical data available in myeloma providing evidence of safety for in vivo HDAC6 inhibition with Acetylon’s lead drug candidate. For more information contact Dr. Kim Hunter-Schaedle at CTF – khs@ctf.org

Close Menu